WASHINGTON, DC, Jul 19, 2008 (MARKET WIRE via COMTEX) -- Speaking at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies at the Gaylord National Resort in Washington, DC, on Friday, July 18, Florida-based cardiologist Dr. Zannos Grekos astounded over 200 physicians with a presentation on the impressive regenerative behavior of pre-engineered adult stem cells injected into patients with cardiomyopathy. The presentation by the lead cardiologist of Regenocyte(TM) Therapeutic (www.regenocyte.com) included a report on the company's post-stem cell treatment results citing an average increase of 21 percent in cardiac ejection rates as well as measurable improvements in a patient's congestive heart failure class status.

"We're able to bring a patient from a Class IV status to a Class II status in less than 180 days," said Grekos commenting on the success rate of Regenocyte patients receiving adult stem cell therapy to repair damage to heart muscle and arteries caused by atherosclerosis, a disease that causes heart muscle disorders and infarction due to plaque formation in the cardiac arteries in over 500,000 Americans.

According to the Congestive Heart Failure (CHF) Classification System by the New York Heart Association, patients suffering from CHF are categorized into four classes based on the disease's degree of severity. Patients in the lowest classification, Class IV, experience increased pulmonary edema, severe shortness of breath, and can be dependent on an implanted defibrillator and/or continuous infusion of Milrinone, a cardiac drug that improves blood flow by chemically increasing a patient's ejection fraction or ventricular blood pumping rate.

"I've seen patients go from an ejection fraction of 28 percent to 49 percent in six months with the stem cell therapy," he told the captive audience. (An ejection fraction of 50 is normal.) "Injecting a patient's own stem cells into damaged tissue is replacing damaged cells with normal functioning cells. At this point, the patient can discontinue Milrinone infusions and potentially the need of an implanted defibrillator."

Immediately following the presentation, over two-dozen physicians insisting on discovering more about his work approached Grekos in the hallway outside the auditorium. The group was particularly fascinated with the center's research proving that adult stem cells have the ability to engraft themselves into areas damaged by myocardial infarction (heart attacks) and turn into new heart cells and new blood vessels.

Dr. Grekos responded to the forum by stating, "Three months after treatment, cardiac nuclear scans of the areas treated reveal reversal of damage. In some cases, it's virtually impossible to identify the problems that existed before therapy. We have shown such improvement in some patients that they were taken off the heart transplant list."

In adult stem cell therapy, a patient's stem cells are extracted through a simple blood draw at the Regenocyte Clinical Center in Florida. The sample is sent to a biotechnology laboratory in Israel where the cells are cultivated and pre-engineered into millions of cardiac regenocytes (living heart repair cells). The patient receives injections of the new cells one week later at one of the clinic's internationally licensed treatment centers. Over the next few months, the cells stimulate tissue re-growth and create greater blood flow to the affected areas. Unlike surgically implanted devices, medications, or organ replacement surgery, using a patient's own stem cells to rebuild damaged heart muscles means there is no possibility of rejection or tumorgenicity (cancer causing).

Dr. Grekos and his colleagues in the world medical field are currently employing adult stem cell therapy and coordinating its application for thousands of American patients who have exhausted all other traditional therapy options. His presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference supports efforts by a global community of doctors that are striving to incorporate adult stem cell therapy into mainstream medicine.

Dr. Zannos Grekos will be hosting several public seminars in Naples, Florida and Hilton Head, South Carolina in August 2008. He will also be a featured lecturer at another World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference in Las Vegas on December 11-14, 2008.

Regenocyte(TM) Therapeutic is an international corporation located in Bonita Springs, Florida. Dedicated to leading the world in providing Adult Stem Cell therapies, Regenocyte(TM) Therapeutic utilizes the most effective and safest technologies and medical procedures in order to prolong and improve the lives of its patients. A video of Dr. Grekos' presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies will be available for viewing on the company's website by August 1st. Additional information on adult stem cell therapy as well as patient video testimonials, and seminar reservation requests can be found at www.regenocyte.com.

SOURCE: Regenocyte(TM) Therapeutic